IMPORTANCE Endovascular therapy (EVT) is the standard of care for select patients who had a stroke caused by a large vessel occlusion in the anterior circulation, but there is uncertainty regarding the optimal anesthetic approach during EVT. Observational studies suggest that general anesthesia (GA) is associated with worse outcomes compared with conscious sedation (CS).
E ndovascular therapy (EVT) is a standard-of-care treatment for selected patients with acute ischemic stroke (AIS) who harbor large vessel occlusions in the anterior circulation and present less than 6 hours from symptom onset. [1] [2] [3] However, numerous questions remain regarding best practices for EVT, including which anesthetic strategy results in the best clinical outcomes.
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Most observational studies report worse outcomes from general anesthesia (GA) than from conscious sedation (CS) during EVT, 4-7 but these results may be confounded by selection bias given that patients with increased stroke severity are more likely to be treated under GA. In addition, retrospective studies do not report specific anesthesia protocols, and only few report details concerning hemodynamic data. Physiological and procedural considerations may potentially favor one approach over another. Performing GA will likely delay procedure initiation due to intubation. Furthermore, GA is often associated with a drop in blood pressure, with the potential for worsening cerebral ischemia. On the other hand, patient motion during CS might impede revascularization and promote procedural complications. Two randomized clinical trials comparing GA and CS during EVT have shown conflicting results. The first trial did not show a difference in the primary end point (with a National Institutes of Health Stroke Scale [NIHSS] score improving on day 2), although the proportion of patients achieving functional independence was higher in the GA arm after 90 days. 8 The second trial found no difference in the 90-day modified Rankin Scale (mRS) score. 9 In light of the discrepancy between these trials and the observational studies, further data are warranted. In the present randomized clinical trialGeneral or Local Anesthesia in Intra Arterial Therapy (GOLIATH)-we aimed to test whether CS or GA reduces infarct growth in patients undergoing EVT for AIS.
Methods

Trial Design
The GOLIATH trial was an investigator-initiated, single-center prospective, randomized, open-label, blinded end-point (or PROBE) evaluation that enrolled patients from March 12, 2015, to February 2, 2017. Patients were randomized to GA or CS in a 1:1 fashion; the flowchart ( Figure 1 ) displays the number of patients screened and included. The trial protocol has been published previously, 10 and the original version is attached as Supplement 1. The ethics committee of the Central Denmark Region approved the study and accepted a waiver of consent before randomization because eligible patients typically were not able to give informed consent and treatment was time critical. Patients or their next of kin were later required to give written informed consent to remain in the trial, and only 1 patient refused to give postrandomization consent because he did not want to undergo repeated magnetic resonance imaging (MRI) scans. No data monitoring board was involved.
Patients and Randomization
We screened all patients presenting to Aarhus University Hospital with symptoms suggestive of AIS as well as patients referred for EVT to the center by 2 primary stroke centers. We included all adult patients (18 years of age or older) who presented with large vessel occlusions in the anterior circulation and in whom groin puncture could be performed within 6 hours from symptom onset or when last seen well. We excluded patients who were intubated at presentation or with a Glasgow Coma Scale score (score range: 3-15, with a lower score indicating lower levels of consciousness) lower than 9 as well as those who were not living independently and had a premorbid mRS score (score range: 0-6, with a lower score indicating independent living) of more than 2. Because the primary trial end point was infarct growth, we required a diffusionweighted imaging (DWI) MRI scan to establish a baseline (pre-EVT) infarct volume. Therefore, patients with a contraindication to MRI were excluded. In addition to the DWI scan, the imaging protocol consisted of a T2*-a T2 fluid attenuated inversion recovery-and an angiography sequence. Imaging time was 11 minutes. Patients with baseline infarcts greater than 70 mL were excluded, given their reduced likelihood for achieving good clinical outcomes. Movement or agitation was not a contraindication for the study. After the qualifying scan, an intravenous tissue plasminogen activator was administered in the absence of a contraindication. Randomization was achieved by a web-based program. Patients were stratified according to age (18-65 years or ≥66 years) and NIHSS score (10-16 or ≥17 points; NIHSS score range: 0-42, with higher scores indicating more severe deficits). Block randomization (with sizes 4, 6, and 8) was performed after stratification. Allocation of block size was also random. The allocation to either GA or CS could not be blinded but was unknown by the imaging core laboratory that evaluated the primary outcome and by the nurse who evaluated the 90-day mRS score.
Anesthesia Protocol
The anesthesia protocol is provided in the eAppendix of Supplement 2.
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Thrombectomy Procedure
All procedures were performed by 1 of 2 neurointerventionists with 8 and 13 years of experience. Use of stent retriever, direct thrombus aspiration, or intra-arterial thrombolysis alone or in combination was at the discretion of the neurointerventionist. In case of a cervical internal carotid artery stenosis or occlusion, stenting was performed when possible. Reperfusion was graded by an independent imaging core laboratory according to the modified Thrombolysis in Cerebral Ischemia (mTICI) scale score (range: 0-no flow beyond the occlusion, 1-minimal reperfusion, 2a-less than 50% of the affected vascular territory reperfused, 2b-greater than 50% reperfusion, and 3-complete reperfusion). Successful reperfusion was defined as mTICI 2b or 3.
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Outcomes and Imaging Analysis
The primary outcome was infarct growth, measured in milliliters. Secondary outcome measures were mRS scores after 90 days, time and blood pressure levels, and safety end points. The mRS score was evaluated at 90 days (80-100 days) after the stroke over the telephone by a certified study nurse who was blinded to randomization.
Infarct size before and after the procedure, mTICI score, and procedural safety measures (dissection, perforation, and clot migration) were evaluated by an independent core imaging laboratory to ensure the unbiased assessment of the primary outcome. Baseline infarct size was determined on DWI or apparent diffusion coefficient imaging. Follow-up scan (preferably MRI) was obtained 48 to 72 hours after symptom onset to avoid false DWI reversal and to minimize early edema. Final infarct size measurement was performed, using a T2 fluid attenuated inversion recovery sequence with additional reference to the DWI or apparent diffusion coefficient imaging, and included regions of hemorrhagic conversion.
Safety outcomes were symptomatic intracranial hemorrhage, 90-day mortality, vessel injury, and clot migration to a previous unaffected territory; all of these outcomes were evaluated by the independent imaging core laboratory. Intracranial hemorrhage was graded on gradient echo imaging with additional reference to the T2 fluid attenuated inversion recovery scan. Given the increased sensitivity of gradient echo imaging for blood products, symptomatic intracranial hemorrhage was defined as type 2 parenchymal hematoma with an associated NIHSS score worsening of 4 or more points (Safe Implementation of Thrombolysis in Stroke-Monitoring Study classification). Type 2 parenchymal hematoma is larger than 30% of the infarcted area with an associated mass effect. Owing to poor medical condition, 3 patients underwent noncontrast computed tomography scan at 48 to 72 hours for determination of final infarct volume and the presence of intracranial hemorrhage. These infarcts were all large and clearly demarcated.
Statistical Analysis
A difference in infarct growth of 10 mL was deemed clinically meaningful and was used for sample size calculation. Based on the assumption of an SD of 20 mL, the planned sample size at the start of the trial was 128 patients. The protocol, which was published after trial initiation, contained 2 errors. First, the sample size calculation used an SD of 25 mL, which yielded 98 patients per arm. Second, these 98 patients were mistakenly taken as the entire sample size. Thus, to preserve the protocol with the original sample size of 128 patients, a 30% attrition rate was added in the protocol. These 2 errors were identified after trial completion. Nevertheless, the originally planned sample size was attained at the end of the trial. Analyses were performed using Stata, version 12.0 (StataCorp LLC) and MedCalc software, version 14.12.0 (MedCalc).
Primary analysis was unadjusted and according to the intention-to-treat principle. Categorical variables were compared using the χ 2 test or Fisher exact test where appropriate, and continuous variables were compared with either the unpaired, 2-tailed t test or Mann-Whitney test, where appropriate. We also evaluated outcomes by patients allocated in a perprotocol (as treated) fashion. Statistical significance was defined as a 2-tailed P < .05.
Results
The first patient was enrolled on March 12, 2015, and the last patient was enrolled on February 2, 2017. In that period, 1501 patients were evaluated for suspected AIS, and EVT was performed on 235 patients. A total of 128 patients were included in the trial. For the entire cohort, the mean (SD) age was 71.4 (11.4) years, and 62 (48.4%) were women and 66 (51.6%) were men. The median NIHSS score was 18 (interquartile 
Primary End Point
Final infarct volume was smaller in the GA group ( .0] mL; P = .10). Assuming a normal distribution, the mean infarct growth for CS was 57.4 mL and for GA was 34.1 mL (difference, 23.2 mL; 95% CI, −6.4 to 52.9).
Secondary Angiographic and Clinical End Points
Successful reperfusion was higher in the GA group than in the CS group (76.9% vs 60.3%; P = .04). Early neurological out- a Age, systolic BP, and MAP at induction and during the procedure were normally distributed. NIHSS scores, time metrics, BPs, and heart rate at groin puncture were not normally distributed. (Table 2) . At 90 days, there was a shift to lower mRS scores in the GA group (Figure 2) . The odds ratio (OR) for a shift to lower mRS scores was 1.91 (95% CI, 1.03-3.56). Functional independence-90-day mRS score of 0 to 2-was nominally more frequent with GA than with CS (OR, 1.90; 95% CI, 0.93-3.90). Table 3) .
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Secondary Time Metrics and Blood Pressure End Points
Significantly more patients in the GA group than in the CS group experienced a decrease of greater than 20% in mean arterial pressure (MAP) (57 patients [87.7%] vs 22 patients [34.9%]; P = .001) (Table 3) . However, when MAP dropped below 70 mm Hg, the duration was nonsignificantly longer for CS patients than for GA patients (6.5 [2-13] minutes vs 2 [1-5.5] minutes; P = .09).
Safety End Points
Four patients (6.3%) in the CS group converted to the GA group due to movement. Two of these patients also vomited, and 1 experienced desaturation due to aspiration.
In the GA group, 4 patients (6.2%) had type 2 parenchymal hematoma hemorrhage and 2 patients (3.1%) were symptomatic. In the CS group, 3 patients (4.8%) had type 2 parenchymal hematoma hemorrhage, of which 1 (1.6%) was associated with clinical deterioration. Mortality rate at 90 days was not significantly different in the GA group than the CS group (7.7% vs 12.7%; P = .35) (eTable in Supplement 2).
Supplementary Analyses
In the per-protocol analysis, in which the 4 patients who crossed over from the CS to the GA group were included in the GA group and the 2 patients with mRS scores greater than 2 before inclusion were excluded, successful reperfusion was no longer significantly higher in the GA group than the CS group 
Discussion
In this single-center randomized clinical trial, the primary outcome of infarct growth during EVT was not significantly different between the GA and CS arms. Nevertheless, at 90 days, improved functional outcomes were seen among patients in the GA group. No clinically meaningful differences in safety end points were seen between the 2 arms. These findings support GA as a viable anesthetic approach during EVT.
Contrary to numerous nonrandomized studies that have reported better outcomes with CS, the GOLIATH trial shows signals in favor of GA for multiple end points. In addition to the lower 90-day mRS scores, the GA arm had numerically smaller infarct growth and larger reductions in NIHSS score between baseline and 24 hours. This result is most likely due to the higher rate of successful reperfusion (mTICI 2b to 3) among patients in the GA group. Similarly, in the Sedation vs Intubation for Endovascular Stroke Treatment (SIESTA) study, the GA arm had a higher rate of functional independence at 90 days and a higher, albeit nonsignificant, rate of mTICI 2b to 3 (an absolute difference of 8.5%). 8 These data seem to support the idea that EVT might be performed with greater technical success when patients are under GA and not moving, but no such 
90-d mRS Score
The shift toward better outcome in the general anesthesia group was significant. The odds ratio for a better outcome was 1.91 (95% CI, 1.03-3.56). Change in NIHSS score after 24 h, median (IQR) −10 (−14 to −5) −7 (−13 to 0) .11
Abbreviations: IQR, interquartile range; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Ischemia; NIHSS, National Institute of Health Stroke Scale.
Research Original Investigation Effect of General Anesthesia and Conscious Sedation on Infarct Growth and Outcomes in Stroke
benefits in terms of reperfusion and functional outcome were seen in the GA arm of the AnStroke trial. 9 In addition, the nonrandomized studies that have reported these data generally found no difference in EVT performance such as procedure duration 12,13 or rate of reperfusion 6,14 under different anesthesia regimens. These variable results may be associated with the differences in institutional or operator experience with performing thrombectomy using CS. At Aarhus University Hospital, prior to the trial, thrombectomy was routinely performed using CS; thus, operator inexperience is unlikely to account for the differences in reperfusion between the trial arms. Taken together, the recent randomized trials of anesthesia for EVT demonstrate that GA does not necessarily lead to worse outcomes after EVT. The marked discrepancy in findings between the randomized and nonrandomized studies highlights the problem of bias, in particular confounding by indication. Patients with AIS who have very poor presentation (eg, severe stroke, respiratory compromise) are not only more likely to have worse outcomes but also more likely to require GA, and these patients were certainly included in the GA cohort of retrospective studies. This finding is illustrated by comparing the intention-to-treat and per-protocol analyses in the GOLIATH trial. In the intentionto-treat analysis, final infarct volumes were larger and clinical outcomes were worse for the CS group. These differences were no longer significant in the per-protocol analysis. The 4 patients who crossed over from the CS to the GA arm had extensive final infarcts (median final infarct volume, 130 mL), supporting the idea that patients with a medical indication for GA are sicker and simply have worse outcomes. This observation was similarly seen in a post hoc analysis of the Interventional Management of Stroke (IMS) III trial, wherein the worse outcomes in the GA group were driven largely by those who had a medical indication for GA. 15 Previous nonrandomized studies tried to adjust for baseline differences in patients under GA and those under CS, 13,16 but it is difficult to remove residual confounding due to unmeasured sources of bias. Possible improvements in GA administration in recent randomized clinical trials might also explain the better outcomes achieved with GA compared with outcomes reported in previous literature. Four main factors have been proposed to explain the association between anesthesia and outcomes after EVT: blood pressure, treatment delay, neuroprotection, and ventilation status.
Blood pressure decreases are more frequent with GA and have been associated with worse EVT outcomes, although optimal blood pressure targets remain unknown. 18 Notably, the blood pressure levels in the MR CLEAN study were generally below recommended values; more than 75% of the patients included in the analysis had a systolic blood pressure lower than 140 mm Hg. All 3 recent anesthesia trials established a goal of intraprocedural systolic blood pressure greater than or equal to 140 mm Hg, which is consistent with recent consensus recommendations. 8,9,21 Blood pressure was lower in the GA arm in both the AnStroke and GOLIATH trials (no difference was seen in the SIESTA trial), but it is conceivable that greater attention to preventing hypotension promoted better neurological outcomes within the trials. A longer delay for patients in the GA group was observed from arrival at the neurointerventional suite to groin puncture. However, the median difference was only 9 minutes. This time delay for induction and intubation is acceptable in the context of the much longer overall time from stroke onset to treatment and from stroke onset to reperfusion, which was not significantly different between the competing arms. This finding was remarkably consistent across the 3 trials, demonstrating the feasibility of rapid anesthesia workflow for GA. There are no conclusive data on neuroprotective properties of anesthetic agents to help with recommending one anesthetic agent over another. In this study, propofol was used as both a general anesthetic and a sedative in the CS group to minimize the confounding effect of different drugs. In anesthetic doses, propofol reduces the cerebral metabolic rate of oxygen with the preservation of flow-metabolism coupling and may increase brain tolerance to ischemic insults. 23 Numerous experimental studies have demonstrated the neuroprotective effects of propofol through different molecular pathways. 24 However, this benefit has not been demonstrated in clinical studies. Volatile anesthetic agents have also been suggested as being of benefit.
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Finally, the influence of ventilation on stroke outcomes is unknown. To our knowledge, no studies have demonstrated the effect of ventilatory status on outcome after thrombectomy. However, in this group of patients with poor cerebral blood flow, it can be argued that hypercapnia may potentially increase blood flow and oxygenation into critically hypoperfused areas. This matter requires further investigation.
Limitations
The primary limitation of the GOLIATH trial is that it was conducted at a single center, which may limit its generalizability to centers that use different approaches to anesthesia and neurointerventional treatment. However, we standardized as much as possible the anesthesia protocol used in this trial by adhering to the recent consensus recommendations of the Society for Neuroscience in Anesthesiology and Critical Care regarding respiratory and hemodynamic values. In addition, the primary end point was infarct growth, and consequently, no definitive conclusions can be drawn regarding clinical outcomes. As mentioned, the difference in reperfusion in favor of the GA arm may reflect the discomfort of local neurointerventionists with treatment using CS. The literature varies on this point, with most studies reporting reperfusion rates to be similar between GA and CS. However, the neurointerventionists at our center are experienced and had used a standard thrombectomy protocol that incorporated CS before the start of the trial. These factors were expected to maximize treatment success in both arms. Despite this limitation, all 3 single-center randomized anesthesia trials found that GA does not lead to worse outcomes. But it should be emphasized that these studies were performed at institutions with easy access to advanced anesthesia care, which might have contributed to the success of GA use.
Another limitation of the GOLIATH trial, and the other trials, is the relatively small sample size, which may potentially cause important differences between the treatment arms to be missed. Indeed, given the observed numerical difference in infarcts growth in favor of GA, our study may have been underpowered for the primary end point. Pooled individual patient data meta-analysis of the anesthesia trials is planned to address this issue.
Conclusions
Performing EVT under GA, compared with CS, does not result in worse tissue or clinical outcomes when using a GA protocol that limits the time delay for intubation (<10 minutes) and blood pressure level within recommended limits (systolic blood pressure >140 mm Hg and MAP >70 mm Hg). 
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Recent retrospective studies have suggested that GA may worsen neurological outcome 29 and increase mortality (7-11). However, National Institute of Health Stroke Score (NIHSS) 30 was higher in the GA group, and GA was reserved for patients who could not cooperate 31 and those with airway obstruction. None of the studies included a specific description of 32 the criteria for selecting either GA or CS. Furthermore, systolic blood pressure below 140 33 mmHg appears to be related to worse outcome (9), but none of the retrospective studies 34 present detailed blood pressure data. Thus, the level of evidence is low and to address 35 this problem, patients subjected to EVT will be randomized to either GA or CS and their 36 outcome will be followed.
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As a standard procedure, Magnetic Resonance Imaging (MRI) will be performed before 
Hypothesis
42
We hypothesize that patients receiving endovascular therapy under CS is associated with 43 a better outcome, i.e. lower mRS and infarct size after EVT.
44
Aim of the study 45 The main objective is to determine whether the use of GA or CS during endovascular clot 46 removal in AIS patients influence patient outcome. Specifically, we will determine whether there is a difference in the primary and secondary outcome measures mentioned below.
48
The two groups will be compared in regards to: 
Material and methods
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Patients with ischemic stroke scheduled for acute EVT will be included in the study. Demographical data: Age, gender, hypertension, diabetes mellitus, smoking, ischemic 116 heart disease, known congestive heart failure, atrial fibrillation. Data measured during procedure: The need to convert to GA from CS (airway, agitation).
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Continuous invasive blood pressure. Blood pressure data are sampled continuously and 126 stored on a laptop. The use of vasopressors (ephedrine/phenylephrine) will be recorded.
A power analysis showed that a sample size of n = 128 would be required in order to 130 detect a 10 ml mean difference (SD 20 ml, alpha 0.05 and power of 0.8) in the volume of 131 infarcted tissue between the GA and the LA group, respectively. We estimate it will take 132 about 2 years to accomplish enrollment.
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All data are entered into a database. Statistical analysis will be performed where we will 134 compare the primary and secondary outcomes in the GA and LA groups. 
Ethics and consent
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Why should this study be conducted as an "Acute Study"
138
The patients all suffer from a large ischemic stroke, which often involve a major part of the 139 brain. Aphasia is a typical symptom at admission, which means that they are unable to Since the majority of the patients are incapacitated at admission and since the treatment is 150 severely time dependent, we found that the conditions for an acute study are fulfilled.
Consent
152
We will randomize to GA or CS without consent. Since there are no national or 153 international guidelines as to weather GA or CS should be offered in this situation and 154 since the focus of the study is to test two different anaesthesia procedures and not drugs, 155 we do not find it necessary to obtain consent from patient or relative prior to EVT. The 156 patients and their relatives will be informed that the patient will be offered EVT, which is 157 our standard procedure.
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After the procedure, the patient will be presented with a consent form with information 159 about the study. We will ask for his acceptance to be in the study. The only thing that will 160 differ for the patient being in the study, is the extra MRI scan to be performed 48-72 hours 161 after the procedure. All other scans, tests and the follow-up are parts of our usual routine.
162
The patient can withdraw consent anytime.
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If the patient is in a state, where we cannot obtain consent, consent will be obtained from The primary analysis will be performed unadjusted and according to the intention-to-treat 240 principle. This means that a cross-over patient from CS to GA will stay in the CS group for 241 analysis. Data will be analyzed using conventional appropriate test statistics stratified 242 according to NIHSS and age depending on the distribution of the individual outcome Mann-Whitney for mRS).
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Supplementary analyses using multivariable regression will be done in order to account for Prior to trial initiation, CS and GA were both standard anesthetic approaches during EVT at our institution. Per our institutional protocol, CS was preferred if patients appeared cooperative, without uncontrolled movement and with a patent airway. Anesthesia was provided by a neuroanesthesiologist and an anesthetic registered nurse.
In the neurointerventional suite, patients in the CS arm received a fentanyl bolus of 25-50µg, which was repeated as necessary. A propofol infusion of 1-2mg/kg/hr. was initiated, and adjusted as required.
For patients in the GA arm, rapid sequence intubation with suxamethonium (bolus 0.5-1mg/kg), alfentanil (bolus 0.02-0.03mg/kg) and propofol (bolus 1-5mg/kg followed by 2-10mg/kg/h) was performed. Endotracheal intubation was followed by mechanical ventilation with attempted normoventilation. Anesthesia was maintained with propofol (2-10 mg/kg/h) and remifentanil (0.2-1 µg/kg/min). For both CS and GA, the final dosage and combination of abovementioned anesthetic drugs were on discretion of the attending neuroanesthesiologist. If possible, patients were extubated in the neurointerventional suite immediately after the procedure.
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Blood Pressure Measurements and Thresholds
Invasive arterial blood pressure measurements including systolic (SBP), diastolic and mean arterial pressure (MAP) were measured every minute throughout the procedure using a radial artery catheter. Following the procedure, the neuroanesthesiologist calculated the number of minutes the patient was below the prespecified blood pressure thresholds and manually recorded blood pressure measurements for every minute during the first 5 minutes followed by measurements for every 5 minutes. Data was stored in a database.
Decreases in blood pressure were treated with vasopressors (ephedrine/phenylephrine) to maintain blood pressure within recommended limits (SBP >140mmHg, MAP >70mmHg).
Patients with Delayed Extubation
Patients were extubated in the neurointerventional suite immediately after the procedure.
However, further sedation and mechanical ventilation was required at the neurointensive care unit for two patients from the GA group and one patient who crossed over from CS to GA group. These patients were extubated after 16, 22 and 72 hours respectively. Reasons for delayed extubation were respiratory insufficiency (n=1), insufficient emergence from anesthesia (n=1) and cerebral hemorrhage (n=1),
Both GA and CS patients were generally observed for two hours in the neurointensive care unit before transfer to the stroke unit.
Anesthetic Doses in the Two Groups
Patients in the GA group were anesthetized with either propofol/remifentanil or propofol/remifentanil/fentanyl. Patients in CS group were sedated with a combination of propofol infusion and bolus fentanyl or fentanyl alone. The choice of deviating from the study anesthesia protocol was at the discretion of the attending anesthesiologist. 
